Hologen, a startup cofounded by former Google CEO Eric Schmidt, is raising a $150 million Series A to develop what it calls “large medicine models”—AI systems intended to model human biological variability and de‑risk late‑stage trials. The company spun out of UK academic centers and has received seed backing from private investors and Schmidt’s family office. Hologen proposes to use large-scale biological and clinical data to predict treatment effects across populations, positioning itself at the intersection of drug development, diagnostics and investment. The pitch reflects investor appetite for AI platforms that promise to shrink clinical uncertainty, but Hologen’s claims will hinge on access to high‑quality clinical data and regulatory acceptance of model‑driven evidence.